Endocrine Abstracts

Patients with endocrine-related cancers are notably at increased risk for developing osteoporosis as a complication from their adjuvant anticancer treatment, especially aromatase inhibitors (AIs) in early breast cancer (EBC) and androgen deprivation therapy (ADT) in early prostate cancer (EPC). AI-induced bone loss (AIIBL) occurs at a rate at least 2-fold higher than bone loss seen in healthy, age-matched postmenopausal women and they have a more than 30% higher risk of fractu...

Introduction: Osteoporosis is characterized by a low bone mass and a microarchiterctural disruption. Ageing and estrogen deficiency are the two most important factors for developing osteoporosis. With advanced age the balance between bone formation and resorption becomes progressively negative and non-bone factors contribute to the increased fracture risk with advancing age. Osteoporotic fractures constitute a major cause of morbidity and mortality in the elderly. Post-menopau...